Related
Biohaven Raises $225 Million in Public Offering
Rare Daily Staff Biohaven tapped the public markets for $225 million to advance its pipeline of therapies […]
Read moreBridgeBio Enters Multi-Year Partnership with Resilience to Advance its Gene Therapy Treatments
Rare Daily Staff BridgeBio Pharma and National Resilience entered into a strategic collaboration to manufacture and advance […]
Read moreRegeneron and Intellia Expand Collaboration to Develop CRISPR-Based Therapies
Rare Daily Staff Regeneron Pharmaceuticals and Intellia Therapeutics expanded their research collaboration to develop additional in vivo […]
Read moreFDA Approves Novo Nordisk’s RNAi Therapy for Rare Kidney Disease
Rare Daily Staff The U.S. Food and Drug Administration approved Novo Nordisk’s Rivfloza to lower urinary oxalate […]
Read moreThe Oxford-Harrington Rare Disease Centre Therapeutics Accelerator Launches
Rare Daily Staff The University of Oxford and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio […]
Read moreGenomics England Names Rare Conditions for Test of WGS as a Newborn Screening Tool
Rare Daily Staff Genomics England published an initial list of 223 rare conditions that will be searched […]
Read moreFDA Grants Rocket Priority Review for Gene Therapy to Treat Rare Immune Disorder
Rare Daily Staff The U.S. Food and Drug Administration granted Rocket Pharmaceuticals Priority Review for its experimental […]
Read moreKate Enters Collaboration with Capsida to Manufacture its Next-Generation Gene Therapies
Rare Daily Staff Strategic partnership leverages Capsida’s next-generation manufacturing capabilities to enable development of KateTx’s gene therapy […]
Read moreMirum Reports Positive Phase 3 Study Results Evaluating Chenodal in Patients with CTX
Rare Daily Staff Mirum Pharmaceuticals reported positive data from the phase 3 RESTORE study evaluating Chenodal tablets […]
Read more